- Home
- XEL vs ARGX Comparison
XEL vs ARGX Comparison
Compare XEL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XEL
- ARGX
- Stock Information
- Founded
- XEL 1909
- ARGX 2008
- Country
- XEL United States
- ARGX Netherlands
- Employees
- XEL N/A
- ARGX N/A
- Industry
- XEL Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XEL Utilities
- ARGX Health Care
- Exchange
- XEL Nasdaq
- ARGX Nasdaq
- Market Cap
- XEL 35.6B
- ARGX 35.2B
- IPO Year
- XEL N/A
- ARGX 2017
- Fundamental
- Price
- XEL $70.84
- ARGX $590.80
- Analyst Decision
- XEL Buy
- ARGX Strong Buy
- Analyst Count
- XEL 15
- ARGX 21
- Target Price
- XEL $66.13
- ARGX $619.79
- AVG Volume (30 Days)
- XEL 4.9M
- ARGX 302.1K
- Earning Date
- XEL 10-31-2024
- ARGX 10-31-2024
- Dividend Yield
- XEL 3.13%
- ARGX N/A
- EPS Growth
- XEL 6.51
- ARGX N/A
- EPS
- XEL 3.37
- ARGX N/A
- Revenue
- XEL $13,763,000,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- XEL $2.89
- ARGX $61.99
- Revenue Next Year
- XEL $7.58
- ARGX $42.48
- P/E Ratio
- XEL $20.81
- ARGX N/A
- Revenue Growth
- XEL N/A
- ARGX 85.56
- 52 Week Low
- XEL $46.79
- ARGX $327.73
- 52 Week High
- XEL $70.42
- ARGX $611.22
- Technical
- Relative Strength Index (RSI)
- XEL 72.29
- ARGX 56.12
- Support Level
- XEL $69.11
- ARGX $558.15
- Resistance Level
- XEL $70.42
- ARGX $592.29
- Average True Range (ATR)
- XEL 1.13
- ARGX 12.42
- MACD
- XEL 0.26
- ARGX -2.11
- Stochastic Oscillator
- XEL 92.82
- ARGX 56.76
About XEL Xcel Energy Inc.
Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US with more than half of its electricity sales coming from carbon-free energy.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.